PrimeraDx Developing Assays for Eli Lilly's Drug Development Programs | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostics firm PrimeraDx today announced a deal with Eli Lilly to develop diagnostics in support of the drug firm's therapeutic development programs.

The multiyear deal calls for the two firms to collaborate on the development of multiplex assays on PrimeraDx's ICEPlex System, an automated, high-throughput real-time PCR and capillary electrophoresis instrument. Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.